|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 EUR | 0.00% |
|
-3.93% | -7.07% |
| 2023 | Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Pangaea Oncology, S.A. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.913537 million compared to EUR 1.1 million a year ago. Revenue was EUR 2.56 million compared to EUR 2.27 million a year ago.
Net loss was EUR 0.919562 million compared to EUR 0.927342 million a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.07% | 53.75M | |
| +1.51% | 42.75B | |
| +48.32% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
PANGAEA ONCOLOGY, S.A. 
